Goldman Sachs’s Synergy Pharmaceuticals SGYP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-722,369
Closed -$82K – 5627
2018
Q4
$82K Buy
722,369
+30,890
+4% +$20.3K ﹤0.01% 5032
2018
Q3
$1.18M Sell
691,479
-82,516
-11% -$148K ﹤0.01% 3947
2018
Q2
$1.35M Sell
773,995
-786,152
-50% -$1.36M ﹤0.01% 3881
2018
Q1
$2.86M Sell
1,560,147
-465,932
-23% -$984K ﹤0.01% 3324
2017
Q4
$4.52M Sell
2,026,079
-1,291,591
-39% -$3.21M ﹤0.01% 3090
2017
Q3
$9.6M Buy
3,317,670
+1,109,945
+50% +$3.79M ﹤0.01% 2582
2017
Q2
$9.8M Buy
2,207,725
+782,648
+55% +$3.23M ﹤0.01% 2521
2017
Q1
$6.64M Buy
1,425,077
+411,699
+41% +$2.39M ﹤0.01% 2700
2016
Q4
$6.17M Buy
1,013,378
+360,831
+55% +$1.89M ﹤0.01% 2869
2016
Q3
$3.6M Buy
652,547
+121,412
+23% +$568K ﹤0.01% 3331
2016
Q2
$2.02M Sell
531,135
-25,493
-5% -$86.4K ﹤0.01% 3616
2016
Q1
$1.54M Buy
556,628
+220,145
+65% +$797K ﹤0.01% 3719
2015
Q4
$1.91M Buy
336,483
+174,745
+108% +$1.07M ﹤0.01% 3677
2015
Q3
$857K Buy
161,738
+21,024
+15% +$163K ﹤0.01% 4623
2015
Q2
$1.17M Buy
140,714
+10,872
+8% +$52.7K ﹤0.01% 4401
2015
Q1
$600K Sell
129,842
-16,364
-11% -$53.2K ﹤0.01% 4953
2014
Q4
$446K Sell
146,206
-18,599
-11% -$55K ﹤0.01% 5389
2014
Q3
$459K Buy
164,805
+111,328
+208% +$404K ﹤0.01% 5357
2014
Q2
$218K Sell
53,477
-10,558
-16% -$44.9K ﹤0.01% 6138
2014
Q1
$340K Buy
64,035
+8,874
+16% +$49.7K ﹤0.01% 5628
2013
Q4
$306K Buy
55,161
+36,801
+200% +$159K ﹤0.01% 5682
2013
Q3
$83K Buy
18,360
+3,521
+24% +$15.8K ﹤0.01% 6209
2013
Q2
$63K Buy
+14,839
New +$74.6K ﹤0.01% 5998

Other funds holding SGYP

Goldman Sachs's SGYP Position: Q1 2019 in Review

Goldman Sachs sold out of Synergy Pharmaceuticals (SGYP) in Q1 2019, closing a stake of 722,369 shares — an estimated $82K sold.

Goldman Sachs first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $9.8M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Goldman Sachs reported no remaining Synergy Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Goldman Sachs sold 722,369 Synergy Pharmaceuticals shares in Q1 2019, an estimated $82K.
  • Goldman Sachs first reported a position in Synergy Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Goldman Sachs's Synergy Pharmaceuticals position peaked at $9.8M in Q2 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals as of Q1 2019.

Based on Goldman Sachs's 13F filing for Q1 2019, filed 15 May 2019.